BiondVax LOGO.png
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
05 juin 2023 07h00 HE | BiondVax Pharmaceuticals Ltd.
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential...
Q2Earth-logo.jpg
Q2Earth Signs Exclusive Worldwide License with Agrarian Technologies for Organic Bio-Stimulants
11 juin 2019 08h30 HE | Q2Earth, Inc
Natural formula to be sold by Q2Earth can replace chemical fertilizers and enhance value of soil and mulch products through proprietary processes Palm Beach, FL, June 11, 2019 (GLOBE NEWSWIRE) --...